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Abstract. Prostate cancer is the second cause of cancer in males. The
prophylactic pelvic irradiation is usually needed for treating prostate
cancer patients with Subclinical Nodal Metestases. Currently, the physi-
cians decide when to deliver pelvic irradiation in nodal negative patients
mainly by using the Roach formula, which gives an approximate estima-
tion of the risk of Subclinical Nodal Metestases.
In this paper we study the exploitation of Machine Learning techniques
for training models, based on several pre-treatment parameters, that
can be used for predicting the nodal status of prostate cancer patients.
An experimental retrospective analysis, conducted on the largest Italian
database of prostate cancer patients treated with radical External Beam
Radiation Therapy, shows that the proposed approaches can effectively
predict the nodal status of patients.
Keywords: Machine Learning, Classification, Medicine Applications
1 Introduction
Prostate cancer is the second cause of cancer in males [14]. External Beam Ra-
diation Therapy (EBRT) has a well established role in the radical treatment
of prostate cancer [1, 2], but some issues still remain to be uniformly defined
amongst Radiation Oncologists. One of these issues is the role of the pelvic irra-
diation. The irradiation of pelvic nodes remains controversial in the treatment
of intermediate and high risk nodes-negative prostate cancer. The main problem
is that microscopic Subclinical Nodal Metestases (SNM) can not be detected by
the available technology: the low sensitivity of computed tomography (CT) and
magnetic resonance imaging (MRI) limits their usefulness in clinical staging [20].
This results in prostate cancer patients that are considered as nodes-negative
even though, in fact, they have SNM.
Even if some retrospective studies [23, 24] showed a significant advantage in
terms of biochemical control for patients having an extended primary tumor and
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a risk > 15% (estimated with Roach formula [22]), other retrospective studies,
that specifically addressed to establish the role of the pelvic irradiation, [3, 16,
18] failed in showing any significant advantage in favour of the pelvic irradiation.
In order to help the clinician in the decision to treat or not pelvic nodes,
many predictor tools have been proposed in the literature, most of them based on
linear regression analyses [22, 20, 17]. One the most diffused methods to predict
the SNM of prostate cancer patients is the Roach formula [22]. The reason of
its success is principally its simplicity, as it is based on only 2 parameters: the
Gleason Score sum (GSsum) and the Prostate Specific Antigen (PSA) level.
GSsum is obtained by the analysis of the specimens of the biopsy: the pathologist
assigns a grade to the most common tumor pattern, and a second grade to the
next most common tumor pattern. The two grades are added together to get
a Gleason Score sum. The PSA is a protein secreted by the epithelial cells of
the prostate gland. PSA is present in small quantities in the serum of men with
healthy prostates, but it is often elevated in the presence of prostate cancer or
other prostate disorders.
The Roach formula is shown in Equation 1. In its last formulation it gives
the estimated risk of SNM and when this risk is bigger than 15-25%, Radiation
Oncologists often deliver EBRT to the pelvic nodes. Despite that, this method
presents some important limits in the more updated and used formulation, the
principal one being the absence of information about the clinical stage of the
tumor, that has been already showed to be an important factor influencing the
risk of nodal involvement [17].
2
3
× PSA+ ([GSsum− 6]× 10) (1)
Other methods, as the Partins Tables [20], do not share the same simplicity
of the Roach formula, but they consider the clinical stage of the tumor. On the
other hand their accuracy is still an argument of discussion [21, 11]. Moreover,
some important limits exists also for the Partins Tables: they consider only a
limited part of the population of prostate cancer patients and, furthermore, it
has been showed that their algorithm overestimate the presence of lymph node
and seminal vesicle involvement in patients with a predicted risk of 40% or more
[15]. This could mean that a large part of patients would be uselessly treated
on the pelvis and exposed to the potential side effects of the pelvic irradiation
(acute and/or chronic colitis, diarrhea, cystitis).
Last but not least, all the proposed algorithms estimates only a rate of risk of
SNM (sometimes with large confidence intervals) and their outputs are not based
on a clear dichotomic yes/not criteria. This leads to different interpretation of
their outcome, that results in different treatments delivered to similar patients.
In this paper we study the exploitation of three Machine Learning (ML)
classification algorithms to define patients presenting a SNM status, which can
not be detected by MRI or CT, for helping the clinician in deciding the treat-
ment of pelvic nodes. The generated models are based on several pre-treatment
parameters of prostate cancer patients.
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The possibility to have a reliable predictor to define the nodal status of
prostate cancer patients could have a potential interest also in the field of Health
Economy: it has been calculated that to not perform a staging abdominal CT in
low risk patients –which would be avoided by exploiting an accurate prediction of
the nodal status of the patients– could reduce medical expenditures for prostate
cancer management by U.S. $ 20 - 50 million a year [20].
2 Methodology
2.1 Data
The Pattern of Practices II was retrospectively analyzed. It is the largest Ital-
ian database including clinical, diagnostic, technical and therapeutic features of
prostate cancer patients treated with radical EBRT (+/- hormonal therapies) in
15 Italian Radiation Oncology centers between 1999 and 2003. A total of 1808
patients were included in this analysis.
The pre-treatment features were chosen considering the “real life” situation
of the Radiation Oncologist visiting for the first time a prostate cancer patient.
Their decision to treat or not the pelvic nodes would be based only on the clinical
stage of the tumor, the total Gleason Score (e.g. 3+4) and the Gleason Score
sum (e.g. 3+4=7), the initial PSA value, the age of the patient and the presence
of an ongoing hormonal therapy. The initial clinical stage of the tumor has been
defined with the TNM system, that describes the extent of the primary tumor
(T stage), the absence or presence of spread to nearby lymph nodes (N stage)
and the absence or presence of distant spread, or metastasis (M stage) [9]. The
domains of the considered variables are defined as shown in Table 1. In this
study the machine learning techniques were used for predicting the value of N:
N+ indicates patients with nodal involvement, N0 indicates that patients that do
not have any nodal involvement.
N+ patients were defined as those with a positive contrast enhanced pelvic
magnetic resonance imaging (MRI) and/or computed tomography (CT) scan;
those showing a nodal only relapse after RT were also classified as N+ (as none
of them received pelvic RT). With these criteria, a total of 55 N+ patients were
identified out of the 1808 patients considered.
Following the D’Amico [8] classification that takes into account the initial
PSA, the GS and the clinical T stage, patients were classified in three prog-
nostically different sets, namely: low, intermediate and high risk. Each category
included, 317, 577 and 914 patients, respectively. Finally, 6/317 (1.9%), 10/577
(1.7%), 39/914 (4.2%) N+ patients were found in the 3 D’Amico sets.
2.2 Classification methods
The selection of the classification techniques to exploit is a fundamental part of
this work. Since the objective of the study is to obtain an automated system
for supporting the physicians in their work, we looked for something that is
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Table 1. The domains of the considered variables on the selected patients. N represents
the nodal status of patients, that is the variable that we want to predict.
Variable name Domain
GS
1+1, 1+2, 1+3, 2+1, 2+2, 2+3, 2+4, 2+5
3+1, 3+2, 3+3, 3+4, 3+5, 4+2, 4+3
4+4, 4+5, 5+1, 5+2, 5+3, 5+4, 5+5
GSum 2 – 10
Age 46 – 86
Initial PSA 0.1 – 1066
T 1, 1a, 1b, 1c, 2, 2a, 2b, 2c, 3, 3a, 3b, 4
Hormonal therapy 9 possible therapies + no therapy
N N+, N0
reliable, allows accurate predictions and, at the same time, it is easy to explain
and to represent. After discussing with Radiation Oncologists and physicians
we observed that they will trust and evaluate the suggestions of the automated
system only if it is possible to understand how the decisions are taken. Mainly
for the latter requirement, we focused our study on decision trees. A model
generated by decision tree approaches can be easily represented, and it is intuitive
to follow the flow of information and to understand how the suggested outcome
is generated.
We considered three machine learning techniques for classification, based on
decision trees, included in the well known tool WEKA [12]: J48 [19], Random
Tree [10] and Random Forest [5]. Even if we are aware of the objective difficulty
for humans to interpret the raw model generated by the Random Forest approach
[4], we believe that it will be possible to represent the models generated by this
classifier in an understandable format. Moreover they have demonstrated to
achieve very good performance in classification [6].
2.3 Experimental design
The classification methods are used for classifying patients as N0 (not affected by
nodal metastasis) and N+ (affected by nodal metastasis). The classes of patients
N0 and N+ are very imbalanced through all the D’Amico categories of risk (low,
medium and high), and in the whole database. The N+ population represents less
then the 4% of the all entire set. For balancing the classes among the considered
data sets we applied three different strategies: oversampling, undersampling, and
a mix of them, as follows.
– A random undersampling of the N0 patients.
– B random oversampling of the N+ patients.
– C random undersampling of the N0 patients and random oversampling of
the N+ patients.
Random oversampling and undersampling techniques were selected due to the
improved overall classification performance, compared to a very imbalanced data
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set, that base classifiers can achieve [13]. Given the fact that it is still not clear
which technique could lead to better performance, we decided to experimentally
evaluate three combinations of them.
The sampling techniques were applied on the different categories of risk, lead-
ing to nine different data sets. The resulting datasets had a distribution of about
40%-60% of, respectively, N+ and N0. Furthermore we generated a further dataset
that considers the whole population of the database. The sampling techniques
were applied also to this dataset.
Each of the selected classifying techniques was trained on the previously
described data sets separately, and the resulting predictive models were then
evaluated using a k-fold cross-validation strategy.
For the Roach formula we considered three different cut-offs: 15, 10 and 5
percent. Using a 5% cut-off corresponds to a pessimistic evaluation of the clinical
data, and leads to overestimate the risk of a patient to be N+, while the 15%
value corresponds to a more optimistic approach. The Roach formula does not
need any training on the data sets and is meant to be used as-is, for this reason
we applied it directly to the original datasets.
3 Results
In Table 2 the results of the comparison between Roach formula and the selected
machine learning algorithms are shown. For the comparison we considered four
different metrics: number of patients classified as false negative, specificity, sen-
sitivity and accuracy of the model. The number of false negative, i.e., patients
N+ classified as N0, is critical. These are patients that require to be treated with
pelvic irradiation but that, according to the classification, will not be treated.
Specificity, sensitivity and accuracy are showed as indexes of the overall quality
of the generated models. They indicate the proportion of patients classified as
N0 which are actually N0 (specificity), the proportion of patients classified as N+
which are actually N+ (sensitivity), and the proportion of the patients correctly
classified, regardless to their class (accuracy).
By analyzing the results shown in Table 2, we can derive some interesting
observations. Regarding the Roach formula, we can derive a precise behaviour.
Its ability in identifying affected patients increases with the category of risk, but
at the same time also the number of false positive increases dramatically. On the
other hand the accuracy, very good in low risk patients, decreases in medium
and high risk patients. The number of false negative rapidly decreases from low
risk to high risk categories, because in the latter the Roach formula is classifying
as affected a significantly large percentage of the population.
As expected, the performance of the machine learning approaches does not
significantly change between the risk categories. On the other hand the sampling
technique used on the data set has a great impact on the overall performance.
The data set obtained by applying only the undersampling (A) usually leads the
algorithms to poor performance, mainly because of the very small populations
of the resulting data sets. The only exception is the decision tree generated by
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Table 2. The results, in terms of number of false negative (2nd column), specificity,
sensitivity and accuracy, achieved by the Roach formula with the different cut-offs and
the selected classification algorithms on low (upper), medium (middle) and high (lower)
risk patients. The numbers in brackets indicate the population of the considered data
set.
Roach cut off False Neg Specificity (%) Sensitivity (%) Accuracy (%)
15% 6 0.0 100.0 98.1
10% 6 0.0 100.0 98.1
5% 6 0.0 87.0 85.8
ML Approaches False Neg Specificity (%) Sensitivity (%) Accuracy (%)
J48 A (12) 6 0.0 50.0 25.0
J48 B (612) 0 100.0 92.5 96.3
J48 C (354) 0 100.0 94.7 97.2
RandomT A (12) 3 50.0 0.0 25.0
RandomT B (612) 0 100.0 94.8 97.4
RandomT C (354) 0 100.0 95.2 97.5
RandomF A (12) 6 0.0 33.3 16.7
RandomF B (612) 0 100.0 98.7 99.4
RandomF C (354) 0 100.0 98.4 99.2
Roach cut off False Neg Specificity (%) Sensitivity (%) Accuracy (%)
15 6 40.0 64.9 64.6
10 3 70.0 48.6 49.0
5 3 70.0 33.4 34.0
ML Approaches False Neg Specificity (%) Sensitivity (%) Accuracy (%)
J48 A (20) 1 90.0 40.0 65.0
J48 B (966) 0 100.0 93.1 96.0
J48 C (433) 0 100.0 97.7 98.9
RandomT A (20) 4 60.0 100.0 80.0
RandomT B (966) 0 100.0 96.5 97.9
RandomT C (433) 0 100.0 97.7 98.9
RandomF A (20) 4 60.0 90.0 75.0
RandomF B (966) 0 100.0 97.7 98.7
RandomF C (433) 0 100.0 99.1 99.5
Roach cut off False Neg Specificity (%) Sensitivity (%) Accuracy (%)
15 3 92.3 20.1 23.2
10 3 92.3 14.5 17.8
5 2 94.9 9.9 13.6
ML Approaches False Neg Specificity (%) Sensitivity (%) Accuracy (%)
J48 A (78) 1 97.4 100.0 98.7
J48 B (1460) 0 100.0 88.6 93.2
J48 C (701) 0 100.0 92.9 96.4
RandomT A (78) 11 71.8 79.5 75.6
RandomT B (1460) 0 100.0 94.9 96.9
RandomT C (701) 0 100.0 96.9 98.4
RandomF A (78) 2 94.9 97.4 96.2
RandomF B (1460) 0 100.0 96.1 97.7
RandomF C (701) 0 100.0 95.4 97.7
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Table 3. The results, in terms of number of false negative (2nd column), specificity,
sensitivity and accuracy, achieved by the Roach formula with the different cut-offs and
the selected classification algorithms on the complete data set. The numbers in brackets
indicate the population of the considered data set.
Roach cut off False Neg Specificity (%) Sensitivity (%) Accuracy (%)
15 15 75.4 44.2 45.1
10 12 80.3 33.4 34.7
5 11 81.2 32.0 32.7
ML Approaches False Neg Specificity (%) Sensitivity (%) Accuracy (%)
J48 A (110) 10 81.8 81.8 81.8
J48 B (3039) 0 100.0 92.1 95.5
J48 C (1489) 0 100.0 91.1 95.5
RandomT A (110) 14 74.6 78.2 76.4
RandomT B (3039) 0 100.0 96.2 97.8
RandomT C (1489) 0 100.0 94.8 97.4
RandomF A (110) 9 83.6 78.2 80.9
RandomF B (3039) 0 100.0 96.9 98.2
RandomF C (1489) 0 100.0 96.3 98.1
the J48 algorithm for the high risk patients, which achieved significant results
in both accuracy and sensitivity. This is a surprising result, given the fact that
the use of the cross-validation technique should avoid (or, at least, significantly
limit) the overfitting issue [13, 7].
Usually the best performance are achieved by the classification models gen-
erated by the random forest algorithm on either B or C data sets. It is also im-
portant to note that all the models generated by the selected machine learning
approaches lead to 0 false negative while exploiting B or C sampling techniques.
In Table 3 the results of the comparison between Roach formula and the
selected machine learning algorithms, on the whole population, are shown. A
striking result is that the number of false negative is still 0 for all the selected
machine learning approaches on the data sets generated by the B or C sampling
techniques. This results is confirmed by the 100.0% specificity value. It should
also be noticed that a very few number of patients that are classified as N+ by
the proposed techniques, are actually N0; this means only a small number of
patients will receive a pelvic irradiation, and it is in contrast with the results
obtained with the classical Roach method, even with the more optimistic cut-off
(15%). Furthermore the overall accuracy is very high.
Regarding the Roach formula, the high number of high risk patients, that
leads the formula to define as N+ a very high percentage of N0 patients (as
shown in Table 2), results in poor performance. It is also disappointing that
many affected patients are classified as N0 even by the most pessimistic cut-off
of the 5%. We experimentally observed that by using smaller cut-offs, almost all
the high risk patients will be considered as N+; considering that they are actually
the 4.2%, this result is not relevant and the corresponding cut-off cannot be use
by physicians for taking every day decisions.
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4 Conclusions and future work
Prostate cancer is the second cause of cancer in males. Radiotherapy has a well
established role in the radical treatment of prostate cancer, but some issues still
remain to be uniformly defined amongst Radiation Oncologists. One of these
issues is the role of the pelvic irradiation and, in particular, when a prostate
cancer patient should or should not receive it. Currently, the decision regarding
the pelvic irradiation is still taken mainly by estimating the risk through the
Roach formula, which is very inaccurate. The main issue of this formula is related
to the small number of pre-treatment parameters that it considers.
In this paper we proposed a different approach, based on three well known
classification algorithms: J48, random tree and random forest. The decision trees
algorithms have been chosen due to their intuitive representation, which could
make them more trustable for the physicians. These techniques have been ex-
ploited for generating a predictive model that will support physicians in taking
every day decisions. In order to test and experimentally evaluate the proposed ap-
proaches we used the largest Italian database of prostate cancer patients treated
with radical EBRT. Given the fact that the classes to predict were very im-
balanced, we applied random oversampling and undersampling techniques for
preprocessing them; this lead to three different data set that were then com-
pared with the Roach formula. The results obtained by the ML algorithms are
significantly better; they show that the decision trees classification algorithms
can be effectively exploited for supporting the physicians in every day work.
The proposed models are usually able to correctly identify all the N+ patients
and, furthermore, to limit the number of N0 patients that will receive a pelvic
irradiation. Moreover, it seems that the application of both undersampling and
oversampling is the best strategy for handling this data.
We see several avenues for future work. Concerning the model generation, we
are interested in evaluating the proposed approaches on different, and possibly
larger, prostate cancer patients databases. We are also interested in studying the
possible differences between different populations of patients (maybe gathered
from different geographical regions) and the generated models. It could happen
that very different populations lead to the generation of significantly different
predictive models; in this case the proposed approach can be explicitly trained
for handling different populations.
On the other hand, we are interested in studying a technique for selecting the
model to exploit for supporting physicians decisions. A possibility could be the
combination of the classifications provided by the models generated by the three
exploited classifiers. Additionally, better results could be achieved by clustering
the patients and selecting, for each cluster, the best performing approach.
Finally, we are planning to make available a decision support system based
on the proposed study. The main features of the DSS that we are designing
are: (i) let clinicians to be able to predict the nodal status of new patients; (ii)
update the patients database by integrating new patients; (iii) keep the predictive
model updated with the new added patients and, (iv) receive feedback from the
community. The proposed enhanced DSS will have an intuitive presentation of
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the models. It will be made available online and via applications for mobile
devices; they are currently extensively used by clinicians in every day work.
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